Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

287600

Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can accurately identify which men with intermediate- or high-risk disease will benefit from adding androgen deprivation therapy (ADT) to standard radiation therapy, a study shows. This Myriad Genetics’ test was found to be superior to other methods at predicting cancer spread (metastasis) in these patients, and thereby at distinguishing those who could avoid ADT. The findings, “Association of the clinical cell-cycle risk score…

You must be logged in to read/download the full post.